Den europeiske union -
norsk -
EMA (European Medicines Agency)
vaxzevria (previously covid-19 vaccine astrazeneca)
astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vaksiner - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. bruk av denne vaksinen skal være i samsvar med offisielle anbefalinger.
Norge -
norsk -
Statens legemiddelverk
soluvit
fresenius kabi norge as - halden - tiaminnitrat / riboflavinnatriumfosfathydrat / nikotinamid / pyridoksinhydroklorid / natriumpantotenat / askorbinsyre / biotin / folsyre / cyanokobalamin - pulver til infusjonsvæske, oppløsning - 2.5 mg / 3.6 mg / 40 mg / 4 mg / 15 mg / 100 mg / 60 mikrog / 0.4 mg / 5 mikrog
Norge -
norsk -
Statens legemiddelverk
tiamin life medical 25 mg/ ml
life medical aps (1) - tiaminhydroklorid - injeksjonsvæske, oppløsning - 25 mg/ ml
Norge -
norsk -
Statens legemiddelverk
tiamin life medical 50 mg/ ml
life medical aps (1) - tiaminhydroklorid - injeksjonsvæske, oppløsning - 50 mg/ ml
Norge -
norsk -
Statens legemiddelverk
tiamin aurora medical 50 mg/ ml
2care4 aps - tiaminhydroklorid - injeksjonsvæske, oppløsning - 50 mg/ ml
Norge -
norsk -
Statens legemiddelverk
tiamin aurora medical 25 mg/ ml
2care4 aps - tiaminhydroklorid - injeksjonsvæske, oppløsning - 25 mg/ ml
Den europeiske union -
norsk -
EMA (European Medicines Agency)
fluenz tetra
astrazeneca ab - a/darwin/9/2021 (h3n2) - like strain (a/norway/16606/2021, medi 355293) / a/victoria/2570/2019 (h1n1)pdm09 - like strain (a/victoria/1/2020, medi 340505) / b/austria/1359417/2021 - like strain (b/austria/1359417/2021, medi 355292) / b/phuket/3073/2013 - like strain (b/phuket/3073/2013, medi 306444) - influensa, human - influensa vaksiner, influensa, levende svekket - prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. bruk av fluenz tetra bør være basert på offisielle anbefalinger.
Den europeiske union -
norsk -
EMA (European Medicines Agency)
memantine mylan
mylan pharmaceuticals limited - memantinhydroklorid - alzheimers sykdom - other anti-dementia drugs, psychoanaleptics, - behandling av pasienter med moderat til alvorlig alzheimers sykdom.
Den europeiske union -
norsk -
EMA (European Medicines Agency)
nyxthracis (previously obiltoxaximab sfl)
sfl pharmaceuticals deutschland gmbh - nyxthracis - anthrax - immune sera og immunglobuliner, - obiltoxaximab sfl is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to bacillus anthracis (see section 5. obiltoxaximab sfl is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.
Den europeiske union -
norsk -
EMA (European Medicines Agency)
livmarli
mirum pharmaceuticals international b.v. - maralixibat chloride - alagille syndrome - other drugs for bile therapy - livmarli is indicated for the treatment of cholestatic pruritus in patients with alagille syndrome (algs) 2 months of age and older.